Shailesh Mistry

Dr. Shailesh Mistry

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
ACA E Cook
A E Cook
SMShailesh Mistry
Shailesh Mistry
KGKaren J Gregory
Karen J Gregory
SFS G B Furness
S G B Furness
PSPatrick M Sexton
Patrick M Sexton
KLKatie Leach
Katie Leach

24 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMShailesh Mistry
Shailesh Mistry
NDNyssa Drinkwater
Nyssa Drinkwater
CRChiara Ruggeri
Chiara Ruggeri
KSKomagal Kannan Sivaraman
Komagal Kannan Sivaraman
SLSasdekumar Loganathan
Sasdekumar Loganathan
SMSheena McGowan
Sheena McGowan
Plasmodium parasites, the causative agents of malaria, have developed resistance to most of our current antimalarial therapies, including artemisinin combination therapies which are widely described as our last line of defense. Antimalarial agents with a novel mode of action are urgently required. Two Plasmodium falciparum aminopeptidases, PfA-M1 and PfA-M17, play crucial roles in the erythrocytic stage of infection and have been validated as potential antimalarial targets. Using compound-bound crystal structures of both enzymes, we have used a structure-guided approach to develop a novel series of inhibitors capable of potent inhibition of both PfA-M1 and PfA-M17 activity and parasite growth in culture. Herein we describe the design, synthesis, and evaluation of a series of hydroxamic acid-based inhibitors and demonstrate the compounds to be exciting new leads for the development of novel antimalarial therapeutics.

1 March 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NDNyssa Drinkwater
Nyssa Drinkwater
NVNatalie B. Vinh
Natalie B. Vinh
SMShailesh Mistry
Shailesh Mistry
RBRebecca S. Bamert
Rebecca S. Bamert
CRChiara Ruggeri
Chiara Ruggeri
PSPeter J. Scammells
Peter J. Scammells

1 February 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AAAlaa Abdul-Ridha
Alaa Abdul-Ridha
LLLaura López
Laura López
PKPeter Keov
Peter Keov
DTDavid Thal
David Thal
SMShailesh Mistry
Shailesh Mistry
ACArthur Christopoulos
Arthur Christopoulos
Benzylquinolone carboxylic acid (BQCA) is an unprecedented example of a selective positive allosteric modulator of acetylcholine at the M1 muscarinic acetylcholine receptor (mAChR). To probe the structural basis underlying its selectivity, we utilized site-directed mutagenesis, analytical modeling, and molecular dynamics to delineate regions of the M1 mAChR that govern modulator binding and transmission of cooperativity. We identified Tyr-85(2.64) in transmembrane domain 2 (TMII), Tyr-179 and Phe-182 in the second extracellular loop (ECL2), and Glu-397(7.32) and Trp-400(7.35) in TMVII as residues that contribute to the BQCA binding pocket at the M1 mAChR, as well as to the transmission of cooperativity with the orthosteric agonist carbachol. As such, the BQCA binding pocket partially overlaps with the previously described "common" allosteric site in the extracellular vestibule of the M1 mAChR, suggesting that its high subtype selectivity derives from either additional contacts outside this region or through a subtype-specific cooperativity mechanism. Mutation of amino acid residues that form the orthosteric binding pocket caused a loss of carbachol response that could be rescued by BQCA. Two of these residues (Leu-102(3.29) and Asp-105(3.32)) were also identified as indirect contributors to the binding affinity of the modulator. This new insight into the structural basis of binding and function of BQCA can guide the design of new allosteric ligands with tailored pharmacological properties.

17 June 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SMShailesh Mistry
Shailesh Mistry
CVCeline Valant
Celine Valant
PSPatrick M Sexton
Patrick M Sexton
BCBen Capuano
Ben Capuano
ACArthur Christopoulos
Arthur Christopoulos
PSPeter J. Scammells
Peter J. Scammells

20 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAlessandro Paiardini
Alessandro Paiardini
RBRebecca S Bamert
Rebecca S Bamert
KKKomagal Kannan-Sivaraman
Komagal Kannan-Sivaraman
NDNyssa Drinkwater
Nyssa Drinkwater
SMShailesh Mistry
Shailesh Mistry
SMSheena McGowan
Sheena McGowan
Malaria is a parasitic disease that remains a global health burden. The ability of the parasite to rapidly develop resistance to therapeutics drives an urgent need for the delivery of new drugs. The Medicines for Malaria Venture have compounds known for their antimalarial activity, but not necessarily the molecular targets. In this study, we assess the ability of the “MMV 400” compounds to inhibit the activity of three metalloaminopeptidases from Plasmodium falciparum, PfA-M1, PfA-M17 and PfM18 AAP. We have developed a multiplex assay system to allow rapid primary screening of compounds against all three metalloaminopeptidases, followed by detailed analysis of promising compounds. Our results show that there were no PfM18AAP inhibitors, whereas two moderate inhibitors of the neutral aminopeptidases PfA-M1 and PfA-M17 were identified. Further investigation through structure-activity relationship studies and molecular docking suggest that these compounds are competitive inhibitors with novel binding mechanisms, acting through either non-classical zinc coordination or independently of zinc binding altogether. Although it is unlikely that inhibition of PfA-M1 and/or PfA-M17 is the primary mechanism responsible for the antiplasmodial activity reported for these compounds, their detailed characterization, as presented in this work, pave the way for their further optimization as a novel class of dual PfA-M1/PfA-M17 inhibitors utilising non-classical zinc binding groups.